Eugeroic

Eugeroics (originally, "eugrégorique" or "eugregoric"),[1] also known as wakefulness-promoting agents and wakefulness-promoting drugs, are a class of drugs that promote wakefulness and alertness.[2][3] They are medically indicated for the treatment of certain sleep disorders including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).[2][3] They generally have a very low addictive potential.[2][3] Eugeroics are also often prescribed off-label for the treatment of EDS in idiopathic hypersomnia,[4] a rare and often debilitating sleep disorder which currently has no official treatments approved by the Food and Drug Administration (FDA).

Eugeroic
Drug class
The chemical structure of modafinil, the prototypical drug of this class.
Class identifiers
Synonymswakefulness-promoting agent
wakefulness-promoting drug
UsePromote wakefulness and alertness
ATC codeN06B
In Wikidata

Modafinil and armodafinil each act as a selective, weak, atypical dopamine reuptake inhibitor (DRI)[2][3] whereas adrafinil acts as a prodrug for modafinil. Other eugeroics include solriamfetol, which acts as a norepinephrine–dopamine reuptake inhibitor (NDRI), and pitolisant, which acts as a histamine 3 (H₃) receptor antagonist/inverse agonist.

Examples

Marketed

Discontinued

Never marketed

In development
gollark: `This egg is covered in The People'ssterious patterns.` <- I did *not* think this through.
gollark: WHY WOULD YOU DO SUCH EVIL THINGS, katze?
gollark: RegexFail™
gollark: `This egg is sliThe People's and blue.`
gollark: Chronos specifically.

See also

Categories
► <a href='/wiki/Category:Drug_classes_defined_by_psychological_effects' title='Category:Drug classes defined by psychological effects'>Drug classes defined by psychological effects</a>
► <a href='/wiki/Category:Drugs_by_psychological_effects' title='Category:Drugs by psychological effects'>Drugs by psychological effects</a>
► <a href='/wiki/Category:Psychoactive_drugs' title='Category:Psychoactive drugs'>Psychoactive drugs</a>

References
  1. Milgram, Norton W.; Callahan, Heather; Siwak, Christina (2006). "Adrafinil: A Novel Vigilance Promoting Agent". CNS Drug Reviews. 5 (3): 193–212. doi:10.1111/j.1527-3458.1999.tb00100.x. ISSN 1080-563X.
  2. "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Retrieved 16 August 2015.
  3. "Nuvigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. April 2015. Retrieved 16 August 2015.
  4. "Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin" (PDF). American Academy of Sleep Medicine (AASM). September 2007.
  5. "What is SUNOSI® (solriamfetol) Treatment ? | SUNOSI® for Patients". www.sunosi.com. Retrieved 2020-01-03.
  6. "How WAKIX Works | WAKIX® (pitolisant) tablets". wakix.com. Retrieved 2020-01-03.
  7. "New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1". www.takeda.com. Retrieved 2019-12-06.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.